|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
9/10/2012 8:53:48 AM
VANCOUVER, B.C., Sept. 10, 2012 (GLOBE NEWSWIRE) -- Cardiome Pharma Corp. (Nasdaq:CRME) (TSX:COM) today noted that the European Society of Cardiology (ESC) has issued updated treatment guidelines for the treatment of adult patients with recent on-set atrial fibrillation, a type of irregular heartbeat. The focused update now includes the intravenous (IV) formulation of BrinavessTM (vernakalant), among other treatments, when pharmacologic cardioversion is preferred, as first line therapy for the cardioversion of atrial fibrillation to normal sinus rhythm in patients with no or moderate structural heart disease. The new guidelines were presented as part of the annual meeting of the European Society of Cardiology Congress in Munich on August 28, 2012 and have been published in the European Heart Journal (Camm et al., (2012), European Heart Journal August 24, 2012).
|
|
|
|
|
|
|
|
|
|
|